These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27015138)

  • 1. Elevated liver enzymes in inflammatory bowel disease: the role and safety of infliximab.
    Parisi I; O'Beirne J; Rossi RE; Tsochatzis E; Manousou P; Theocharidou E; Hamilton M; Murray C; Epstein O; Burroughs AK
    Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):786-91. PubMed ID: 27015138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Onset Autoimmune Hepatitis during Anti-Tumor Necrosis Factor-Alpha Treatment in Children.
    Ricciuto A; Kamath BM; Walters TD; Frost K; Carman N; Church PC; Ling SC; Griffiths AM
    J Pediatr; 2018 Mar; 194():128-135.e1. PubMed ID: 29274889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study.
    Koller T; Galambosova M; Filakovska S; Kubincova M; Hlavaty T; Toth J; Krajcovicova A; Payer J
    World J Gastroenterol; 2017 Jun; 23(22):4102-4111. PubMed ID: 28652663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease.
    Shelton E; Chaudrey K; Sauk J; Khalili H; Masia R; Nguyen DD; Yajnik V; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2015 May; 41(10):972-9. PubMed ID: 25756190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver enzyme profiles after initiating biological treatment in children with inflammatory bowel diseases.
    Räisänen L; Nikkonen A; Kolho KL
    J Pediatr Gastroenterol Nutr; 2024 Sep; 79(3):583-591. PubMed ID: 38946705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
    Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
    Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis.
    Sokolove J; Strand V; Greenberg JD; Curtis JR; Kavanaugh A; Kremer JM; Anofrei A; Reed G; Calabrese L; Hooper M; Baumgartner S; Furst DE;
    Ann Rheum Dis; 2010 Sep; 69(9):1612-7. PubMed ID: 20448284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asymptomatic hyperCKemia During Infliximab Therapy in Patients With Inflammatory Bowel Disease.
    Theodoraki E; Orfanoudaki E; Foteinogiannopoulou K; Koutroubakis IE
    Inflamm Bowel Dis; 2018 May; 24(6):1266-1271. PubMed ID: 29718260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
    Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events.
    Khanna R; Feagan BG
    Expert Opin Drug Saf; 2015 Jun; 14(6):987-97. PubMed ID: 25819509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does infliximab short infusion have a beneficial impact on the quality of life in patients with inflammatory bowel diseases? A single centre prospective evaluation.
    Principi M; Losurdo G; La Fortezza RF; Lopolito P; Lovero R; Grillo S; Bringiotti R; Ierardi E; Di Leo A
    J Gastrointestin Liver Dis; 2015 Jun; 24(2):165-70. PubMed ID: 26114175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 1-year prospective study of the effect of infliximab on bone metabolism in inflammatory bowel disease patients.
    Veerappan SG; Healy M; Walsh B; O'Morain CA; Daly JS; Ryan BM
    Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1335-44. PubMed ID: 27508327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six Cases of Lung Injury Following Anti-tumour Necrosis Factor Therapy for Inflammatory Bowel Disease.
    Lee HS; Jo KW; Shim TS; Song JW; Lee HJ; Hwang SW; Park SH; Yang DH; Kim KJ; Ye BD; Byeon JS; Myung SJ; Kim JH; Yang SK
    J Crohns Colitis; 2015 Nov; 9(11):1053-7. PubMed ID: 26221002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab-Associated Immunomediated Hepatitis in Children With Inflammatory Bowel Disease.
    Mostamand S; Schroeder S; Schenkein J; Miloh T
    J Pediatr Gastroenterol Nutr; 2016 Jul; 63(1):94-7. PubMed ID: 26835903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands.
    de Vries HS; van Oijen MG; de Jong DJ
    Drug Saf; 2008; 31(12):1135-44. PubMed ID: 19026030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients.
    Andrade P; Santos-Antunes J; Rodrigues S; Lopes S; Macedo G
    J Gastroenterol Hepatol; 2015 Nov; 30(11):1591-5. PubMed ID: 25967740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
    Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy.
    Duron C; Goutte M; Pereira B; Bommelaer G; Buisson A
    Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):705-11. PubMed ID: 25856689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab-induced autoimmune hepatitis.
    Jenkins A; Austin A; Hughes K; Sadowski B; Torres D
    BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 34031069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.